Abuse deterrent formulations of opioid medications (ADOs) may help curtail the widespread abuse, misuse, and diversion of these products.With the exception of oxycodone, little information exists regarding the impact of abuse deterrent products on reducing abuse/misuse of opioid products.Studies have shown that Medicaid patients are dispensed opioids at a higher rate, abuse opioids at a higher rate, and experience more morbidity and mortality than other populations. In this study we seek to quantify misuse, abuse, dependence, and health resource use in a Medicaid patient sample prescribed an abuse deterrent formulation of extended release morphine (EMBEDA®) or non-abuse deterrent extended release morphine (ERM).
Predicting Screen Failure Rates of Human Abuse Potential Studies
Human Abuse Potential (HAP) studies are required for New Drug Approvals of all drugs that have a potential psychoactive effect. The steps of…
Targeting Patients In A Complex Phase II Rheumatoid Arthritis Study
Targeting Patients In A Complex Phase IIa Rheumatoid Arthritis Study.
Oral Abuse Potential of Benzhydrocodone, a Novel Prodrug of Hydrocodone
Hydrocodone bitartrate (HB) and acetaminophen (APAP) combination products are known to be abused via oral, intranasal, and intravenous…